The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis by Spalinger, Marianne R & Scharl, Michael
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
The role for protein tyrosine phosphatase non-receptor type 22 in regulating
intestinal homeostasis
Spalinger, Marianne R; Scharl, Michael
Abstract: Inflammatory bowel disease represents a chronic intestinal inflammation. Recent knowledge
suggests a crucial role for genetic, immunological and bacterial factors in inflammatory bowel disease
pathogenesis. Variations within the gene locus encoding PTPN22 have been associated with inflammatory
bowel disease. PTPN22 is critically involved in controlling immune cell activation and thereby plays an
important role in maintaining intestinal homeostasis. Although in B and T cells the mechanism showing
how PTPN22 affects cell signalling pathways is well studied, its role in myeloid cells remains less defined.
Regulation of the innate immune system plays an essential role in the intestine, and levels of PTPN22 in
myeloid cells are drastically reduced in the intestine of inflammatory bowel disease patients. Therefore,
additional studies to define the role of PTPN22 in myeloid cells might clearly enhance our understanding
of how PTPN22 contributes to intestinal homeostasis.
DOI: https://doi.org/10.1177/2050640615600115
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136227
Accepted Version
Originally published at:
Spalinger, Marianne R; Scharl, Michael (2016). The role for protein tyrosine phosphatase non-receptor
type 22 in regulating intestinal homeostasis. United European Gastroenterology Journal, 4(3):325-332.
DOI: https://doi.org/10.1177/2050640615600115
 1 
The role for protein tyrosine phosphatase non-receptor type 22 in 
regulating intestinal homeostasis 
 
 
 
 
Marianne R. Spalinger1, Michael Scharl1,2 
 
 
Author affiliations: 1Division of Gastroenterology and Hepatology, University 
Hospital Zurich, Zurich, Switzerland, 2Zurich Center for Integrative Human 
Physiology, University of Zurich, Zurich, Switzerland 
 
 
Correspondence to: PD Dr. Michael Scharl, MD, Division of Gastroenterology and 
Hepatology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. 
Phone: +41-44-255-9519, Fax: +41-44-255-9497. E-mail: michael.scharl@usz.ch  
 
 
Funding:  This work was supported by research grants from the Swiss National 
Science Foundation (SNF) to MS (Grant No. 314730-146204 and Grant No. 
CRSII3_154488/1). 
 
 
Conflict of interest: The authors have no conflict of interest. 
 
 
 2 
ABSTRACT 
Inflammatory bowel disease (IBD) represents a chronic intestinal 
inflammation. Recent knowledge suggests a crucial role for genetic, immunological 
and bacterial factors in IBD pathogenesis. Variations within the gene locus encoding 
PTPN22 have been associated with IBD. PTPN22 is critically involved in controlling 
immune cell activation and thereby plays an important role in maintaining intestinal 
homeostasis. Although in B and T cells the mechanism how PTPN22 affects cell 
signalling pathways is well studied, its role in myeloid cells remains less defined. 
Regulation of the innate immune system plays an essential role in the intestine, and 
levels of PTPN22 in myeloid cells are drastically reduced in the intestine of IBD 
patients. Therefore, additional studies to define the role of PTPN22 in myeloid cells 
might clearly enhance our understanding how PTPN22 contributes to intestinal 
homeostasis.  
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INTRODUCTION 
Inflammatory bowel disease (IBD) is comprised of two major sub-forms, 
called Crohn’s disease (CD) and ulcerative colitis (UC). While UC is a continuous 
inflammation restricted to the colon, CD is a discontinuous inflammation that can 
affect the whole GI tract. Apart from chronic and relapsing intestinal inflammation, a 
characteristic feature of UC and CD are the presence of extra-intestinal 
manifestations, such as inflammation in the joints, eyes or the skin1. 
According to current knowledge, genetic, immunological and bacterial factors 
contribute essentially to the pathogenesis of IBD2. A dysfunctional immune response 
of the innate as well as the acquired immune system to commensal microbes results in 
either excessive up- or impaired down-regulation of inflammatory events, what finally 
drives the development of chronic intestinal inflammation2, 3. The predispositions for 
these aberrant immune responses are genetically determined and genome wide 
association studies (GWAS) identified single nucleotide polymorphisms (SNPs) in 
more than 160 gene loci being associated with IBD4. Many of the identified risk genes 
are critically involved in controlling host immune responses to the intestinal 
microbiota, i.e. they mediate bacterial recognition5, induction of antimicrobial factors 
or activation and modulation of innate as well as adaptive immune responses5, 6. 
 
Phosphorylation and dephsophorylatio represents a fundamental mechanism 
for the activation and inactivation of intracellular signalling molecules7. Especially in 
immune cells, phosphorylation/dephosphorylation of signalling molecules is crucial 
for an adequate response towards extracellular stimuli such as presence of antigens or 
cytokines8-12. While phosphorylation is mediated by protein kinases, 
dephosphorylation is carried out by a large number of different protein 
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phosphatases13. One important family of phosphatases are the protein tyrosine 
phosphatases (PTPs). Members of this family play an essential role in the regulation 
of critical cell signalling events, i.e. proliferation, differentiation and cell survival14. 
In the past decade, GWAS revealed a strong association between SNPs in the 
gene locus encoding one of these PTPs, namely protein tyrosine phosphatase non-
receptor type 22 (PTPN22), and several inflammatory disorders, including CD 4, 15, 
UC 4, 15, systemic lupus erythematodes (SLE) 16, rheumatoid arthritis (RA) 17, 18, type 
1 diabetes (T1D) 19 and many others 20. Nowadays, genetic variants in the PTPN22 
locus are considered one of the most important, non-HLA-associated genetic risk 
factors for the onset of autoimmune disorders21, what highlights the importance of 
PTPN22 in regulating immune responses. In this review we summarize the most 
recent knowledge about the role of PTPN22 in the pathogenesis of chronic intestinal 
inflammation, in particular IBD. 
 
Variants in the gene locus encoding PTPN22  
Two SNPs within the gene locus encoding PTPN22 are associated with 
inflammatory disorders, namely SNP rs2476601 (C1858>T) and SNP rs33996649 
(G788>C). Presence of rs2476601 results in the substitution of Arginine 620 with a 
tryptophan residue in the protein product (referred to as 620W variant). SNP 
rs33996649 mediates substitution of arginine 263 with a glutamine residue (referred 
to as 263Q variant).  
Arginine 263 lies within the catalytic domain of the PTPN22 protein product 
and substitution with a glutamine residue results in a decreased phosphatase activity 
22. Of note, presence of the 263Q variant reduces the risk to develop SLE and RA 22, 23 
and protects from UC onset15, however not much is known about the effects of this 
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variant on cellular mechanisms and immune functions. For this reason, this variant 
will not be discussed more into detail in this review.  
Presence of the PTPN22 620W variant is associated with an increased risk for 
RA17, 18, SLE16, T1D19, but interestingly reduces the risk to develop CD 15, 24. The 
PTPN22 protein has three domains, an N-terminal catalytic domain, followed by a 
linker domain, and a C-terminal Proline rich domain25. Arginine 620 lies within the 
C-terminal Proline rich domain that seems to be important for determining substrate 
specificity26. Although the 620W variant has initially been described to result in a true gain-of-function protein product27, the functional consequence of this substitution has recently been debated. Initial studies by Vang et al. demonstrated a gain-of-function in inhibition of the T cell receptor (TCR) signalling cascade resulting from the 620W substitution27, and this variant features increased in vitro de-phosphorylation capacity27. The enhanced phosphatase activity might result from reduced PTPN22 phosphorylation at an inhibitory residue28, 29. Other mechanism to explain the enhanced phosphatase activity of the PTPN22 620W variant, include increased substrate interaction due to enhanced localization in lipid rafts26, and/or reduced interaction with Csk30, 31. Current hypothesis suggest that in resting T cells Csk binds to PTPN22 and sequesters it away from its substrates in the TCR signalling cascade26. 620W PTPN22, however, seems to be unable to interact with Csk, resulting in increased interaction of PTPN22 with its substrates, finally resulting in gain-of-function inhibition of TCR signalling26. In contrast to the gain-of-function hypothesis, one 
study using mice that express PTPN22 619W (the murine orthologue of the disease 
associated human PTPN22 620W) indicates that this variant might result in reduced 
protein stability and therefore finally in a net loss-of-function effect32. However, this 
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finding could not be confirmed in other studies using an independently generated 
PTPN22 619W knock-in strain33. Interestingly, in both studies using PTPN22 619W 
knock-in mice, presence of the PTPN22 619W variant resulted in increased T cell 
responses33, an effect that contradicts the gain-of-function hypothesis.   
 
In an approach using in vivo silencing of PTPN22 by siRNA interference, 
phenotypically opposite effects of the siRNA treatment on B cell differentiation was 
reported when compared with the effects of the PTPN22 620W allele in patients34. 
This further supports the gain-of-function hypothesis. As initially suggested by Dai et 
al in their report using PTPN22 619W mice33, Wang et al recently proposed that the 
620W variant might be an altered-function, rather than a loss- or gain-of function 
variant35, proposing altered substrate specificity of this variant as possible mechanism 
for the observed effects35. Although convincing, this hypothesis still lacks further evidence to draw a final conclusion.   
In addition to the two already mentioned variants, two far less studied 
polymorphisms in PTPN22 have been reported. One is a rare missense variant that 
results in a substitution of Histidine 370 with a Glutamine residue (H370N variant) 
reported by Rivas et al, the other a SNP in the promoter region of PTPN22 (SNP ID 
rs2488457). The H370N variant might result in increased risk to develop IBD36, but 
apart from the study by Rivas et al, this variant has not been described further and 
nothing is known about the functional consequences of the H370N variant. Presence 
of rs2488457 on the other hand has been reported to enhance the risk to develop 
rheumatoid arthritis in Asian populations37, 38, but seems not to have important effects 
in Caucasians39. Also for rs2488457 very little is known about functional 
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consequences. We will not address these two less described variants later in this 
review. 
 
 
The role of PTPN22 in lymphocytes 
PTPN22 is expressed in both, myeloid and lymphoid immune cells, but barely 
present in non-hematopoietic cell types40. Given the strong association with 
inflammatory diseases, several studies addressed the role of PTPN22 in immune cell 
signalling. In T cells, PTPN22 activity attenuates T cell antigen receptor (TCR) 
signalling by interacting with and de-phosphorylation of the TCR associated kinases 
lymphocyte-specific protein tyrosine kinase (Lck) and zeta-chain associated protein 
(ZAP)-7041, 42. Further interaction partner of PTPN22 in the TCR signalling cascade 
include VAV, and Csk 42, 43. As described above, interaction with Csk is suggested to 
have important consequences on the ability of PTPN22 to suppress TCR signalling26. 
While Csk sequesters wild-type PTPN22 and prevents binding of PTPN22 to its 
substrates, Csk cannot bind PTPN22 620W, what finally results in increased 
suppression of TCR signalling26. Consistent with the gain-of-function theory, 
presence of the 620W variant results in reduced T cell receptor signalling in T1D 
patients and healthy individuals29, while PTPN22 deficient T cells are hyper-
responsive to TCR ligation44. Further, overexpression of PTPN22 in the T cell 
compartment results in attenuated TCR signalling, and in a non-obese diabetic (NOD) 
mouse model is able to reduce autoimmune diabetes incidence45. PTPN22 deficient 
mice in contrast display increased levels of effector and memory T cells, but 
interestingly do not show signs of autoimmunity44. Of note, the same phenotype on 
effector/memory T cells has been observed in mice expressing the 619W variant in 
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PTPN22, an aspect arguing for a loss-of-function effect of the variant32, 33. The lack of 
autoimmunity in PTPN22 deficient mice was explained in additional studies, which 
revealed that these mice harbour increased numbers of regulatory T cells46, 47. The 
study by Brownlie et al reported that PTPN22 deficient Treg have enhanced 
suppressor functions and thereby are able to counteract the increased T cell activation 
found in PTPN22 deficient effector T cells46. However, the study by Maine et al did 
not find intrinsic differences in Treg function47. While Maine et al, attributed the 
increased number of Treg to an enhanced thymic output of Treg47, Brownlie et al did 
not see differences in Treg output from the thymus, but rather suggested increased 
proliferation/induction of peripheral Treg as source for enhanced Treg numbers46. Of 
note, mice expressing the PTPN22 619W variant showed no difference in Treg 
induction or regulatory capacity33, an effect arguing against the loss-of-function 
theory.  
 
In a further study to investigate the role of PTPN22 in autoimmunity, Main et 
al addressed the effect of PTPN22 deficiency on germinal center reactions, where B 
cells are activated by follicular T helper cells (Tfh) to differentiate into antibody 
producing plasma cells. In this study, they found increased numbers of Tfh cells, but 
in contrast to conventional Treg, follicular regulatory cells (Tfr) were not enhanced. 
Ultimately, this resulted in increased B cell activation and antibody production, 
mediating pronounced arthritis severity in a mouse model engineered to develop T 
helper cell dependent arthritis48. However, in a mouse model of SLE, PTPN22 
deficiency had no effect on disease incidence or severity, although PTPN22 deficient 
animals still showed enhanced levels of Tfh cells and enhanced antibody 
production49. In general, the effect of PTPN22 on autoimmunity seems to depend on 
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the genetic background, as presence of PTPN22 619W results in signs of systemic 
autoimmunity in a mixed genetic background, but is lost when the mice are 
backcrossed into a pure C57BL/6 background33.    
 
Presence of the PTPN22 620W variant leads to an increased frequency of 
auto-reactive B cell clones in healthy patients 50, 51 and T1D patients 51. Several 
studies argue that this is the result of B cell intrinsic defects 21, such as enhanced 
survival of auto-reactive B cells at the transition from immature to naive B cells 50, 51 
due to alterations in B cell receptor (BCR) signalling 50, 51. A more recent study 
however claims that this effect might result from changes in follicular Th cell 
activation, which drives altered activation of B cells in germinal centres, rather than 
from a B cell intrinsic effect 48. Nevertheless, Dai et al demonstrated that B cell 
specific overexpression of the PTPN22 619W variant suffices to induce enhanced GC 
proliferation and the emergence of autoimmunity in a mixed genetic background33, 
clearly indicating a B cell intrinsic role for PTPN22. In contrast, the study by Maine 
et al nicely shows that follicular T helper cells are important drivers of aberrant 
germinal centre B cell development in PTPN22 deficient mice48. 
 
Recently, an important role for innate type lymphoid cells (ILC) has been 
implicated in the pathogenesis of intestinal inflammation52. So far, very little is 
known about the role of PTPN22 in these cells. Although very high expression of 
PTPN22 is found in NK cells40, which are regarded as one subset of ILCs53, the 
consequences of altered PTPN22 function in NK cells, or other types of ILCs remains 
elusive. It is also not known if other ILCs beside NK cells express PTPN22. 
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PTPN22 in myeloid immune cells 
Most studies addressing PTPN22 function have been carried out in 
lymphocytes, but PTPN22 expression is very high in other immune cell types as well, 
including neutrophils, macrophages, and dendritic cells (DC) 21, 40. We have 
demonstrated that loss of PTPN22 in monocytes results in profound changes in IFN-γ-
induced signalling with reduced STAT1, but strongly enhanced p38 activation, 
ultimately resulting in drastically enhanced IL-6 secretion together with reduced IL-
12 levels 54. Loss of PTPN22 resulted in an altered response to the bacterial product 
muramyl-dipetide (MDP) causing not only enhanced autophagy induction but also 
increased secretion of pro-inflammatory IL-6 and IL-855. Hence loss of PTPN22 in 
myeloid immune cells results in an increase in the secretion of pro-inflammatory 
cytokines (Figure 1). 
 
Wang et al. demonstrated that presence of the PTPN22 620W variant results in 
impaired type-1 IFN production upon TLR4 ligation 35. Of note, this effect seems to 
be independent of PTPN22 phosphatase activity but relays on direct interaction of 
PTPN22 with TRAF3, which represents the most important signalling molecule in 
terms of type-1 IFN induction downstream of TLR456. While the common PTPN22 
variant interacts with TRAF3 and mediates its K63 ubiquitination, cells expressing 
the disease-associated 620W variant fail to induce TRAF3 ubiquitination upon TLR4 
ligation, what ultimately results in decreased type-1 IFN production35. Consistent with 
the fact that direct interaction of PTPN22 and TRAF3 is required for efficient type-I 
IFN production, similar effects were observed in PTPN22 deficient cells35. This 
indicates a loss-of-function effect of the variant in this particular aspect of PTPN22 
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function. The effect of loss of PTPN22 on type-1 IFN production was confirmed in an 
additional study, where enhanced IFN-α production was found upon TLR7 ligation in 
PTPN22 deficient plasmacytoid dendritic cells49. While Wang et al did not find a 
difference in NF-κB-mediated cytokine secretion upon TLR4 ligation35, in our hands, 
loss of PTPN22 resulted in increased secretion of NF-κB-mediated IL-8 upon MDP 
treatment55. This discrepancy cannot be fully explained with the current body of 
knowledge, but might result from differences in the activation of additional signalling 
pathways that indirectly influence NF-κB activity.  
 
Further studies demonstrated that loss of PTPN22, as well as the presence of the 
620W variant, promotes differentiation of monocytes into pro-inflammatory 
macrophages 57, and DC from PTPN22 mice expressing the 619W variant expressed 
higher levels of the co-stimulatory molecule CD40 and induced higher proliferation of 
OT-II T cells in in vitro co-culture experiments32. 
 
 
PTPN22 in IBD patients 
The PTPN22 620W variant is regarded as a general autoimmune risk allele, as 
it is associated with increased risk to develop several autoimmune disorders, such as 
RA, SLE or T1D 20. Interestingly, presence of the PTPN22 620W variant at the same 
time results in a reduced risk to develop CD15. This opposite effect on intestinal 
inflammation in contrast to autoimmune diseases evokes the question about the 
underlying mechanism(s). We found that PTPN22 expression is reduced in the 
intestine of both, UC and CD patients. This reduction was found to be mainly due to a 
dominant down-regulation of PTPN22 in cells of the monocyte/macrophage linage 
 12 
(CD68+ cells), whereas we only observed a subtle difference in PTPN22 expression 
in T or B cells54. We further showed that TNFα and IL-1β, two cytokines highly 
elevated in active lesions of IBD patients, mediate reduction of PTPN22 levels in 
monocytes/macrophages54, however, the mechanism of this down-regulation still 
remains elusive. The specific reduction of PTPN22 in the myeloid cell compartment 
in the intestine of IBD patients indicates an important role of PTPN22 in these cells 
for maintaining intestinal homeostasis (Figure 2). On the other hand, in classical 
autoimmune diseases, such as RA, SLE or T1D, T and B cells play a predominant 
role58, 59. This contrasting contribution of the innate vs. the adaptive arm of the 
immune system to disease onset might explain why PTPN22 variants reduce the risk 
for IBD, while in classical autoimmune disorders the same variant is associated with 
an enhanced risk. 
 
 
PTPN22 in experimental colitis 
Although several genetic association studies revealed an association between 
PTPN22 and IBD susceptibility15, 60, only a few studies addressed its functional role 
during intestinal inflammation. One study showed that in a T cell mediated colitis 
model, where naïve T cells were transferred into immune-deficient mice, naive 
PTPN22 deficient T cells induced aggravated intestinal inflammation and tissue 
damage 46. Interestingly, transfer of PTPN22 deficient regulatory T cells – but not 
transfer of wild-type regulatory T cells – rescued this phenotype 46. This effect is 
attributed to increased suppressive competence of PTPN22 deficient regulatory T 
cells 46. A recent study further revealed that PTPN22 deficient naive T cells 
proliferate faster, acquire full effector functions and loos self-tolerance in immune 
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deficient hosts 61. This explains how PTPN22 deficient T cells are able to mediate 
increased inflammation when injected into lymphopenic mice.  
 
The important protective role of PTPN22 during intestinal inflammation has 
further been confirmed in two independent studies using a dextran-sodium sulphate 
(DSS) induced model of acute colitis35, 57. In both studies, loss of PTPN22 resulted in 
increased reaction to DSS with aggravated weight loss and enhanced colitis severity 
35, 57. The enhanced colitis susceptibility has been attributed to altered TLR4 
signalling and reduced type I interferon production in one study 35, or altered 
macrophage polarization in the other report, respectively 57. As type I interferon 
protect mice from colitis62, the effect of loss of PTPN22 on type I interferon might –at 
least in part – explain why PTPN22-/- mice suffer from more severe colitis and how 
reduction of PTPN22, as observed in IBD patients, might contribute to disease 
pathogenesis. However, the cell-type specific contribution to intestinal inflammation 
has not been directly addressed. We have observed that PTPN22 deficiency results in 
reduced myelin peroxidase activation and decreased granulocyte infiltration into the 
inflamed colon during DSS colitis (own unpublished data), suggesting a role for 
PTPN22 in mediating granulocyte function / recruitment.  
 
As PTPN22 expression is reduced mainly in myeloid cells within the intestine 
of IBD patients54, transfer of PTPN22 deficient T cells or colitis induction in a setting 
where PTPN22 is missing in all cells, might be an incomplete approach to address 
PTPN22 function during intestinal inflammation. Additional in vivo studies including 
PTPN22 deficiency specifically in non-lymphoid immune cells would greatly 
improve our general understanding on the role of PTPN22 in IBD.  
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 In summary, IBD patients feature decreased levels of PTPN22 in myeloid 
cells in the intestine54. Several studies demonstrated, that loss of PTPN22 in myeloid 
cells changes the response towards pro-inflammatory cytokines and bacterial 
products35, 54, 55, 57. Hence, reduction of PTPN22, as observed in IBD patients 
importantly affects the cytokine balance within the inflamed intestine, ultimately 
promoting disease persistence and progression (Figure 3). 
 
Future directions and concluding remarks 
PTPN22 is critically involved in controlling immune cell activation and 
thereby plays an important role in maintaining intestinal homeostasis. Although in B 
and T cells the mechanism how PTPN22 affects cell signalling pathways is well 
studied, its role in myeloid cells remains less defined, and very little is known about 
its function in ILC. Regulation of the innate immune system plays an essential role in 
the intestine, and levels of PTPN22 in myeloid cells are drastically reduced in the 
intestine of IBD patients. Therefore, future studies to define the role of PTPN22 in 
myeloid cells, as well as in innate lymphoid cell will clearly enhance our 
understanding how PTPN22 contributes to intestinal homeostasis.  
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FIGURE LEGENDS 
 
Figure 1: PTPN22 controls IFN-γ and MDP induced signaling cascades. 
Loss of PTPN22 promotes p38 MAPK and canonical (p50/p65) NF-κB activation, 
and increases MDP induced autophagy, while ERK activation is reduced. On the 
other hand, loss of PTPN22 results in decreased STAT1 activity. Taken together, 
these events cause a highly imbalanced cytokine secretion pattern. ERK: 
Extracellular-signal regulated kinase; ICAM-1: intercellular adhesion molecule 1; 
IFN: interferon; IFNR: interferon receptor; IL: Interleukin; MCP-1: monocyte 
chemoattractant protein 1; mMDP: muramyl-dipeptide; NF-κB: nuclear factor κB; 
NOD2: nucleotide oligomerization containing protein 2; p38: mitogen activated 
protein kinase p38; STAT1; signal transducer and activator of transcription 1; TNFα: 
tumor necrosis factor alpha. 
 
 
Figure 2: Reduced PTPN22 expression in IBD patients. In the healthy 
intestine, high levels of IL-10 and TGF-β result in high expression of PTPN22 in all 
immune cells. Upon epithelial damage, the pro-inflammatory cytokine milieu results 
in reduced PTPN22 expression specifically in cells of the myeloid linage, while 
lymphoid cells still express high amounts of PTPN22. B: B cell, DC: dendritic cell; 
IFN: interferon; M/MF: Macrophage; M1: inflammatory macrophage; T: T cell; 
TNFα: Tumor necrosis factor alpha. 
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Figure 3: Proposed mechanism, how PTPN22 is involved in IBD 
pathogenesis. Inflammatory insults result in high levels of TNFα, IFN-γ and IL-1β. 
TNFα and IL-1β reduce PTPN22 expression in myeloid immune cells. Upon loss of 
PTPN22, monocytes/macrophages secrete increased levels of IL-6 and IL-8 and 
differentiate preferentially into pro-inflammatory macrophages. The increased 
expression of co-stimulatory molecules on DC results in an enhanced activation of the 
adaptive immune system. B: B cell, DC: dendritic cell; IFN: interferon; M: 
Macrophage: Minf: inflammatory macrophage; T: T cell; TNFα: Tumor necrosis 
factor alpha. 
